Notice: This company has been marked as potentially delisted and may not be actively trading. NASDAQ:PHAS PhaseBio Pharmaceuticals (PHAS) Stock Price, News & Analysis Add Compare Share Share Stock Analysis Stock AnalysisBuy This Stock About PhaseBio Pharmaceuticals Stock (NASDAQ:PHAS) 30 days 90 days 365 days Advanced Chart Remove Ads Get PHAS alerts:Sign Up Key Stats Today's Range N/A50-Day Range N/A52-Week Range N/AVolume9.65 million shsAverage Volume848,888 shsMarket Capitalization$3.50 millionP/E RatioN/ADividend YieldN/APrice TargetN/AConsensus RatingN/A Company OverviewPhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company, which engages in the development and commercialization of novel therapies for cardiovascular diseases. The firm's pipeline includes: bentracimab (PB2452), a novel reversal agent for the antiplatelet therapy ticagrelor, pemziviptadil (PB1046), a once-weekly vasoactive intestinal peptide receptor agonist for the treatment of pulmonary arterial hypertension, and PB6440, an oral agent for the treatment of resistant hypertension. The company was founded by Ashutosh Chilkoti and Clay Bernardin Thorp in January 2002 and is headquartered in Malvern, PA.Read More… Remove Ads PhaseBio Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks7th Percentile Overall ScorePHAS MarketRank™: PhaseBio Pharmaceuticals scored higher than 7% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's OpinionN/AAnalyst RatingN/A Consensus RatingThere is not enough analysis data for PhaseBio Pharmaceuticals. Earnings and Valuation0.0 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of PhaseBio Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of PhaseBio Pharmaceuticals is -0.03, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings. Short InterestN/AShort Interest LevelN/A Short InterestThere is no current short interest data available for PHAS. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPhaseBio Pharmaceuticals does not currently pay a dividend.Dividend GrowthPhaseBio Pharmaceuticals does not have a long track record of dividend growth. Sustainability and ESG4.5 / 5Environmental Score-0.91 Short InterestThere is no current short interest data available for PHAS. News and Social Media0.6 / 5News SentimentN/A News Coverage This WeekMarketBeat has tracked 1 news article for PhaseBio Pharmaceuticals this week, compared to 0 articles on an average week.MarketBeat Follows1 people have added PhaseBio Pharmaceuticals to their MarketBeat watchlist in the last 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, PhaseBio Pharmaceuticals insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 9.90% of the stock of PhaseBio Pharmaceuticals is held by insiders.Percentage Held by Institutions49.02% of the stock of PhaseBio Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about PhaseBio Pharmaceuticals' insider trading history. Receive PHAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for PhaseBio Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address PHAS Stock News HeadlinesTicagrelor antidote safely, effectively restores platelet function and treats bleedingApril 1 at 9:09 AM | msn.comMedPharm appoints Bill Humphries as new CEOFebruary 6, 2025 | msn.comTrump… a socialist? Trump’s Final Reset Inside the shocking plot to re-engineer America’s financial system…and why you need to move your money now.April 1, 2025 | Porter & Company (Ad)PhaseBio Pharmaceuticals Inc.October 19, 2024 | thestreet.comPhiladelphia-area life sciences industry nears 900 layoffs since 2022October 11, 2024 | bizjournals.comPhaseBio Pharmaceuticals, Inc. (PHASQ)August 3, 2024 | ca.finance.yahoo.comVelia Therapeutics Appoints Michael York as Chief Business OfficerDecember 14, 2023 | finance.yahoo.comAlcami Announces CEO TransitionJune 5, 2023 | finance.yahoo.comSee More Headlines PHAS Stock Analysis - Frequently Asked Questions How were PhaseBio Pharmaceuticals' earnings last quarter? PhaseBio Pharmaceuticals, Inc. (NASDAQ:PHAS) announced its quarterly earnings data on Wednesday, November, 10th. The company reported ($0.66) EPS for the quarter, missing analysts' consensus estimates of ($0.59) by $0.07. The firm had revenue of $0.34 million for the quarter, compared to analyst estimates of $2.67 million. When did PhaseBio Pharmaceuticals IPO? PhaseBio Pharmaceuticals (PHAS) raised $66 million in an initial public offering (IPO) on Thursday, October 18th 2018. The company issued 5,000,000 shares at $12.50-$14.00 per share. Citigroup, Cowen and Stifel acted as the underwriters for the IPO and Needham was co-manager. What other stocks do shareholders of PhaseBio Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that PhaseBio Pharmaceuticals investors own include Sorrento Therapeutics (SRNE), SCYNEXIS (SCYX), Axsome Therapeutics (AXSM), VBI Vaccines (VBIV), Outlook Therapeutics (OTLK), Viking Therapeutics (VKTX) and Anavex Life Sciences (AVXL). Company Calendar Last Earnings11/10/2021Today4/01/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PHAS CIK1169245 Webwww.phasebio.com Phone(610) 981-6500FaxN/AEmployees60Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($2.13) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-131,070,000.00 Net Margins-12,572.13% Pretax Margin-12,572.13% Return on EquityN/A Return on Assets-174.38% Debt Debt-to-Equity RatioN/A Current Ratio0.47 Quick Ratio0.47 Sales & Book Value Annual Sales$818,000.00 Price / Sales0.00 Cash FlowN/A Price / Cash FlowN/A Book Value($1.93) per share Price / BookN/AMiscellaneous Outstanding Shares49,858,000Free Float44,922,000Market Cap$3.50 million OptionableNot Optionable Beta2.57 (Almost) Everything You Need To Know About The EV MarketLooking to profit from the electric vehicle mega-trend? Enter your email address and we'll send you our list of which EV stocks show the most long-term potential.Get This Free Report This page (NASDAQ:PHAS) was last updated on 4/1/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredA market crash is coming—here’s whenThe stock market cycle I've used to identify the most likely day of the next market crash is the exact same in...Chaikin Analytics | SponsoredTrump Allies Confirm Exec Order 14024 Triggers Dollar CollapseExecutive Order 14024 is paving the way for irreversible damage to the dollar's value—threatening your wealth,...Priority Gold | SponsoredElon Musk Confirms: Tesla’s Optimus is Replacing Workers… and Heading to MarsMusk confirmed that SpaceX's Starship will carry Optimus to Mars in 2026 as part of an autonomous mission to h...InvestorPlace | SponsoredRetirement Nightmare? It’s Already Happening.The market is on edge. Every day, another company slashes its dividend, leaving investors scrambling. Intel...Investors Alley | SponsoredNew “Trump” currency proposed in DCA former U.S. Presidential Advisor has come forward with a stern warning to investors: “Get out of tech, no...Paradigm Press | SponsoredBrace Yourself for Jeff Bezos’ “Amazon Helios”Jeff Bezos quietly backing world-changing tech (not AI) The Amazon founder is quietly advancing a radical t...Stansberry Research | SponsoredIs Fort Knox Hiding Less Gold Than We Think? Find Out What That Means for YouWith gold prices recently soaring to record highs over $3,000 an ounce, and central banks rushing to accumulat...The Oxford Club | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding PhaseBio Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share PhaseBio Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.